Altman Z″
Needs current assets and current liabilities.
A plain-language read of the business, how it actually earns, where the edge is, and the economics of every reported segment — taken from the annual report and investor presentation, not a one-line industry label.
Trading at 128.5x earnings against its own median of 35.0x: 2.7 standard deviations above its usual range. This compares the company with its own history, not with other companies.
How to read this: Price shows the closing price with its 50-day (amber) and 200-day (grey) averages; bars at the bottom are daily volume, green on up days and red on down days; dashed lines mark the 52-week high and low. vs Nifty 50 starts both at 100 so you can see which did better over the period. P/E shows what the market paid for each rupee of profit, inside the band it usually trades in. Drawdown shows how far below its best price the share has been. Hover anywhere for the numbers on that day.
The three to six things that actually matter about this company, each with the exact filing and note it came from — never a fact without the context that makes it meaningful.
What the numbers mean when read together — computed from the filings, not a score.
Capital work-in-progress has stayed high (18% of fixed assets) without converting to productive assets — worth checking whether projects are genuinely progressing.
Why this reading: Noted with caution — worth watching, but not yet conclusive on its own. Business has ups and downs; one soft reading is not a verdict.
CWIP ₹773 cr vs ₹423 cr two years earlier, against fixed assets ₹4,371 cr. Perennial CWIP that never becomes a fixed asset can hide stalled projects or capitalised costs that should have been expensed.
Operating cash is 182% of trailing profit — the earnings are converting to real cash, not just accruals.
Why this reading: A positive signal: cash conversion at or above ~0.9 means reported profit is showing up as actual cash.
Operating cash ₹1,624 cr against trailing net profit ₹890 cr. Consistent conversion near or above 1.0 is a hallmark of genuine earnings.
Both revenue and profit grew over the last year (22.6% and 114.6%) — growth is translating to the bottom line.
Why this reading: A positive signal in the numbers, shown for balance alongside the concerns.
Trailing revenue ₹7,269 cr, trailing profit ₹1,090 cr. Profit growing at least as fast as revenue indicates operating leverage or pricing power.
Free cash flow swings between positive and negative across the cycle.
Why this reading: Surfaced for context, not as a concern — it only becomes meaningful if it persists or pairs with other signals.
Latest ₹560 cr, negative in 4 of 12 years.
Every score below is calculated here from the reported numbers — none of it is asserted. Open the notebook at the foot of the section to see each formula with this company's figures in it.
Needs current assets and current liabilities.
Piotroski F-Score — fundamental momentum — Joseph Piotroski, University of Chicago, 2000, in a study of whether accounting signals could improve returns among cheap stocks.
Nine yes-or-no tests across profitability, leverage and operating efficiency. Each pass scores one. It asks a narrow question: is this business getting better or worse on its own terms, year over year?
How to read it7 or more suggests improving fundamentals; 3 or fewer suggests deterioration. It measures direction, not quality — a weak company improving can score higher than a strong one holding steady.
Where it failsA single year of comparison, so one unusual year distorts it. Says nothing about valuation, competitive position or management. Piotroski designed it to rank already-cheap stocks, not to judge a company in isolation.
Needs trade receivables, current assets, other expenses.
Accruals are -7.4% of assets. Free cash flow negative in 4 of 12 years.
DuPont decomposition — Devised inside the DuPont Corporation in the 1920s and still the standard way to read a return on equity.
Splits return on equity into its three sources, so the same headline number can be traced to very different businesses.
How to read itA 20% ROE built on margin and turnover is a different proposition from a 20% ROE built on 3× leverage. The first survives a downturn; the second amplifies it.
Where it failsA single year. Negative equity makes it meaningless. Leverage is structural for lenders, so the third term carries no signal there.
Capital and revenue are growing at broadly similar rates — the asset base is being used, not just added to.
cumulative operating cash flow ÷ cumulative net profit
₹6,966 cr ÷ ₹4,928 cr, over 12 years
1.41×
Above 1.0 means cash exceeds reported profit — the healthier reading.(net profit − operating cash flow) ÷ average total assets
(₹890 − ₹1,624) cr ÷ average assets
-7.4%
Negative means cash exceeded profit — the healthier reading. Positive above ~10% is where accruals start to dominate earnings.net margin × asset turnover × leverage
13.1% × 0.65 × 1.98
16.8%
Splits ROE into whether returns come from operations or from borrowing.EBIT ÷ finance cost
₹1,353 cr ÷ ₹171 cr
7.91×
How many times operating profit covers the interest bill.borrowings ÷ net worth
₹2,518 cr ÷ ₹5,300 cr
0.48×
Read against the sector — infrastructure carries more than software.growth in fixed assets + CWIP, against growth in revenue
capital +30% vs revenue +13%, FY2023 to FY2026
17pp gap
Money going in far faster than revenue coming out. For an incubator this is expected — the test is whether it eventually converts.Needs more balance-sheet detail (only 3 of 6 flags testable).
NOPAT over equity plus debt less cash, at a notional 25% tax. Incremental ROIC is the return on money put in since then — the number that decides whether growth creates value or consumes it.
Return on invested capital, and incremental ROIC — Standard in corporate finance; the incremental form was popularised by Michael Mauboussin as the test of whether growth creates value.
ROIC measures what the business earns on all the capital it employs — equity plus debt, less cash. Incremental ROIC asks a sharper question: what has it earned on the money put in since a chosen year?
How to read itROIC comfortably above the cost of capital — call it 11–13% in India — means growth compounds. Below it, growth consumes. Incremental below headline means recent investment is earning less than the legacy business.
Where it failsDistorted in the year of a large acquisition. Understated for companies mid-build, where capital is deployed but capacity has not yet been commissioned — an incubator will look poor until it does not.
Read downward. Cash can cover EBITDA and still not survive capex — the third rung is where a capital-hungry business shows itself.
The earnings quality ladder — Not a named model — the standard sequence an analyst walks when testing whether reported profit is real.
Three ratios read in order, each stricter than the last.
How to read itRead downward. Each rung failing where the one above passed tells you exactly where the cash is going.
Where it failsA single year of heavy capex depresses the third rung legitimately. Judge it across a cycle.
The growth rate that makes today's market value equal the discounted cash flows, at a 11.5% discount rate and 4.0% terminal growth. Not a forecast — the arithmetic of what is already in the price. Compare it with what the business has actually delivered.
Reverse DCF — the growth already in the price — A standard inversion of discounted cash flow, used to avoid the forecasting problem entirely.
Instead of forecasting cash flows and deriving a value, it takes today's market value as given and solves for the growth rate that would justify it. The output is not a view — it is the arithmetic of what the market is currently assuming.
How to read itCompare it with what the business has actually delivered. A price implying 30% a year against a decade of 15% is a demanding assumption; the reverse is a modest one.
Where it failsUseless when free cash flow is negative or unusually depressed, which is common mid-capex. Highly sensitive to the discount rate — a point either way moves the answer materially.
Against a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%.
Cost of debt — Interest expense over average borrowings — the effective rate the company actually pays.
What the lenders charge, which is a market verdict on credit quality that no rating agency delay affects.
How to read itAgainst a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%. Read the direction over years as much as the level.
Where it failsUnderstated where a large share of interest is capitalised into projects under construction. Not meaningful for lenders, where interest is cost of goods.
Some figures appear twice on this page with different values. That is not an error — they sit on different bases. The live feed reports a rolling twelve months; everything computed here comes from the last audited statements. Both are shown so you can see which is which.
Where the two disagree, every model, screen and ratio computed on this page uses the filed figure, because the rest of the page is on that basis.
Models that need these lines are withheld rather than estimated: net worth, current assets, current liabilities, trade receivables, inventory, net block. Nothing on this page is back-solved from a figure the company did not publish.
Each framework below is a set of stated, mechanical criteria from published work, run against this company's own filed numbers. Passing or failing a screen is not a verdict — different frameworks disagree by design, and that disagreement is itself informative.
Benjamin Graham's stated criteria for a defensive stock, applied to the filed numbers. A company failing several is not disqualified — Graham designed these to be deliberately strict.
Two ratios only: what the business earns on its capital, and what you pay for those earnings. Designed to be ranked across a universe rather than read in isolation.
The fundamental half of William O'Neil's framework. The market and leadership components are judgement calls and are not scored here.
The characteristics long-term holders commonly look for: cash-backed earnings, high returns on capital, and debt that never forces a decision.
Median of the companies we hold in the same sector (Healthcare). Every figure on both sides is the live feed's trailing twelve months, so the two are measured the same way whatever depth of extraction this company has had. A number only means something next to something else — expensive against the market and cheap against peers are different facts.
Bars are revenue; the line is net margin. Revenue rising while the line falls is the shape worth noticing.
Operating cash first, then what the business spent and raised.
One year is a snapshot. These are the two lines that matter across a cycle.
Rising debtor or inventory days against flat sales is the earliest visible sign of stress.
Set your own assumptions and watch the numbers move. A scenario calculator — the outputs are the arithmetic of your inputs.
One canonical set of figures — the same numbers used everywhere else on this page and on the screener.
How the register has moved over recent quarters — the direction matters more than the level.
Promoter held steady from 27.59% to 27.47% across these quarters.
FII rose from 26.17% to 28.00% across these quarters.
MF rose from 8.53% to 10.15% across these quarters.
Other trimmed from 37.71% to 34.38% across these quarters.
Where cash gets stuck. A rising inventory or debtor line against flat sales is the earliest sign of trouble in the numbers.
| Measure | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor days
How long customers take to pay | 113 | 102 | 99 | 100 | 96 | 120 | 132 | 115 |
| Inventory days
How long stock sits before it sells | 201 | 234 | 266 | 293 | 222 | 277 | 285 | 317 |
| Payable days
How long the company takes to pay suppliers | 144 | 159 | 199 | 146 | 94 | 158 | 141 | 170 |
| Cash conversion cycle
Debtor + inventory − payable days | 170 | 177 | 166 | 247 | 224 | 240 | 276 | 263 |
| Working capital days | 6 | 15 | 43 | 43 | 59 | 42 | 43 | 58 |
| ROCE %
Return on capital employed | 8.0% | 14.0% | 40.0% | 26.0% | 23.0% | 7.0% | 9.0% | 18.0% |
| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| R&D, % of sales | 4.3% | — | — |
| Gross margin | 63% | 62.7% | 59.9% |
| ANDA approvals | 2 | — | — |
| ANDAs pending | 2 | — | — |
| CDMO Small Molecules Revenue (₹ crore) | 875 | 835 | 471 |
| CDMO Bio Revenue (₹ crore) | 29 | 35 | 47 |
| Affordable Medicines API Revenue (₹ crore) | 625 | 654 | 617 |
| Affordable Medicines FDF Revenue (₹ crore) | 677 | 502 | 518 |
| EBITDA Margin | 34.5% | 31.8% | 26% |
| ARV Combined Revenue (₹ crore) | 735 | 669 | 733 |
| CDMO Small Molecules Revenue (₹ crore) | 875 | 835 | 471 |
| Total Small Molecule API Reactor Volume (KL) | 9,000 | — | — |
| Solid Phase Peptide Synthesis Volume (L) | 16,000 | — | — |
From the quarterly results and the earnings call, read by FinMinutes. Latest quarter, read in full.
Read using the Pharmaceuticals framework (named in the filing read). Primary valuation lens: P/E excluding one-time exclusivity gains.
Read more closely in this sector: Status of each US-filed plant · Price erosion stated · One-product dependence.
The shape of the business over time (annual) — read the direction, not the single print.
| Line | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue from operations | 4,814 | 4,936 | 6,041 | 5,041 | 5,554 | 6,813 |
| Other income | 23 | 14 | 6 | 24 | 75 | 47 |
| Depreciation | 205 | 251 | 324 | 385 | 430 | 480 |
| Finance cost | 68 | 102 | 165 | 183 | 216 | 171 |
| Profit before tax | 1,301 | 1,084 | 1,109 | 236 | 484 | 1,182 |
| Net profit (owners) | 984 | 832 | 793 | 162 | 358 | 890 |
| EPS (₹) | 18.33 | 15.40 | 14.67 | 2.98 | 6.64 | 16.46 |
Exceptional items, total income and EBITDA are read from the filed statements.
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,224 | 1,195 | 1,440 | 1,195 | 1,224 | 1,415 | 1,720 | 1,570 | 1,653 | 1,778 | 1,812 | 2,026 |
| Other Income | 2 | 2 | 19 | 3 | 5 | 9 | 59 | 10 | 27 | 6 | 12 | 9 |
| Expenses | 1,037 | 1,014 | 1,198 | 1,024 | 1,045 | 1,130 | 1,300 | 1,187 | 1,250 | 1,298 | 1,299 | 1,388 |
| Depreciation | 93 | 98 | 102 | 106 | 108 | 106 | 110 | 117 | 120 | 121 | 122 | 124 |
| Finance cost | 42 | 51 | 50 | 49 | 53 | 58 | 56 | 52 | 40 | 39 | 40 | 42 |
| Profit before tax | 54 | 35 | 107 | 18 | 23 | 131 | 312 | 224 | 270 | 327 | 361 | 481 |
| Net Profit | 37 | 23 | 75 | 13 | 20 | 93 | 233 | 162 | 194 | 252 | 282 | 362 |
| EPS | 0.69 | 0.43 | 1.40 | 0.23 | 0.37 | 1.71 | 4.33 | 3.02 | 3.61 | 4.66 | 5.17 | 6.80 |
| Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 107 | 107 | 108 | 108 | 108 | 108 |
| Reserves | 2,490 | 3,244 | 3,930 | 4,003 | 4,365 | 5,192 |
| Borrowings | 1,482 | 1,777 | 2,015 | 2,577 | 2,764 | 2,518 |
| Net block | 2,171 | 2,652 | 3,409 | 3,890 | 4,123 | 4,371 |
| CWIP | 362 | 813 | 551 | 423 | 458 | 773 |
| Investments | 3 | 31 | 50 | 124 | 233 | 309 |
| Total Assets | 5,751 | 6,968 | 7,660 | 8,387 | 9,336 | 10,511 |
| Line | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 733 | 911 | 994 | 666 | 602 | 1,624 |
| Cash from investing | -941 | -914 | -997 | -822 | -680 | -1,086 |
| Cash from financing | 255 | 30 | -27 | 250 | 39 | -525 |
| Free cash flow | 49 | 34 | 6 | -10 | 61 | 560 |
| Net change in cash | 47 | 27 | -30 | 93 | -39 | 13 |
Cash from operations is the number profit has to answer to. Free cash flow is what remains after the business pays for its own growth.
The part no one reads: the auditor's opinion, the contingent liabilities buried in the notes, the covenants, and the claims in the deck placed beside the figures that test them.
Where analysts pressed management on the earnings call, and exactly how management answered — the questions that were hardest to answer are usually the ones that matter.
These are coverage counts, not ratings. Each one asks a fixed set of questions of the filings and reports how many the company answered. A company that discloses nothing counts nothing here — that is a statement about the disclosure, not about the business.
The same read, applied to the companies this one competes with.
Laurus Labs Ltd. reported revenue of ₹2,206 cr for July to September 2026, +33.4% on the year and +8.9% on the quarter. That is faster than this quarter has grown in recent years (+17.5% on average), so the year-on-year number is not just the season. It is the highest quarterly revenue in the last 12 quarters on record. Over the last four quarters revenue comes to ₹7,823 cr, +23.0% on the four before.
Operating profit (EBITDA) was ₹750 cr, a margin of 34.0%, +962 bps on the year and +251 bps on the quarter. It is the widest margin of the last 8 quarters (range 20.1% to 34.0%). Operating costs grew +16.5% against revenue growth of +33.4%, so more of each rupee of sales reached operating profit.
Net profit was ₹436 cr, +124.3% on the year and +20.5% on the quarter, with earnings per share of ₹8.17. Profit before other income, one-offs and tax grew faster, at +138.4%; other income, one-offs or tax held the headline back. The tax rate of 26% is in line with its recent average. Profit over the last four quarters totals ₹1,332 cr, +95.2% on the four before.
Of the 13 companies in Pharmaceuticals that have reported Q2 FY27 so far, Laurus Labs Ltd. ranks 1st on revenue growth; the sector median is +11.8%. Its margin moved +962 bps on the year against a sector median of −60 bps.
Pharma quarters swing with US generic launches and price erosion, while India formulations grow more steadily. Currency gains and other income can be material, so headline profit needs a check against operating profit.
On earnings per share of ₹24.81 over the last four quarters, the stock at ₹2,454.00 trades at 98.9 times trailing earnings.
No check fired. That is a statement about the checks below, not a verdict on the company.
Profit is backed by cash: operating cash flow exceeded profit.
Source: Cash flow statement
Could not run on this quarter: Exceptional items that recur, IPO money used as stated, Related-party transactions, Promoter pledges and allotments, Earlier promises against delivery. The filing did not carry these lines.
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
| Balance sheet | Sep '26 | Last year end | Change |
|---|---|---|---|
| Trade receivables | ₹2,242 cr | ₹2,155 cr | ▲ 4.0% |
| Inventory | ₹2,659 cr | ₹2,342 cr | ▲ 13.5% |
| Cash | ₹24.5 cr | ₹113 cr | ▼ 78.3% |
| Bank balances | ₹4.3 cr | ₹1.0 cr | ▲ 312.5% |
| Long-term borrowings | ₹553 cr | ₹611 cr | ▼ 9.5% |
| Short-term borrowings | ₹1,937 cr | ₹1,786 cr | ▲ 8.4% |
| Trade payables | ₹1,301 cr | ₹1,252 cr | ▲ 3.9% |
| Net block | ₹3,847 cr | ₹3,873 cr | ▼ 0.7% |
| Capital work in progress | ₹1,282 cr | ₹773 cr | ▲ 65.8% |
| Equity | ₹6,181 cr | ₹5,431 cr | ▲ 13.8% |
| Total assets | ₹11,514 cr | ₹10,511 cr | ▲ 9.5% |
| Cash flow, year to date | This year | Last year |
|---|---|---|
| Operating cash flow | ₹805 cr | ₹1,093 cr |
| Capital expenditure | −₹864 cr | −₹489 cr |
| Investing cash flow | −₹863 cr | −₹477 cr |
| Financing cash flow | −₹30.5 cr | −₹668 cr |
| Dividends paid | −₹64.8 cr | −₹43.1 cr |
Operating cash flow was 1.01× profit. Receivables at 97 days of sales (−19 days against the last year end). Inventory at 115 days of sales (−11 days).
No emphasis of matter.
Filing p. 6
Board approved the appointment of Mr. Kundan Kumar Jha as Joint Company Secretary, being a Key Managerial Personnel of the Company, with effect from November 1, 2026. (p. 1)
| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| R&D, % of sales | 4.3% | — | — |
| Gross margin | 63% | 62.7% | 59.9% |
| ANDA approvals | 2 | — | — |
| ANDAs pending | 2 | — | — |
| CDMO Small Molecules Revenue (₹ crore) | 875 | 835 | 471 |
| CDMO Bio Revenue (₹ crore) | 29 | 35 | 47 |
| Affordable Medicines API Revenue (₹ crore) | 625 | 654 | 617 |
| Affordable Medicines FDF Revenue (₹ crore) | 677 | 502 | 518 |
| EBITDA Margin | 34.5% | 31.8% | 26% |
| ARV Combined Revenue (₹ crore) | 735 | 669 | 733 |
| CDMO Small Molecules Revenue (₹ crore) | 875 | 835 | 471 |
| Total Small Molecule API Reactor Volume (KL) | 9,000 | — | — |
| Solid Phase Peptide Synthesis Volume (L) | 16,000 | — | — |
Read using the Pharmaceuticals framework (named in the filing read). Primary valuation lens: P/E excluding one-time exclusivity gains.
Read more closely in this sector: Status of each US-filed plant · Price erosion stated · One-product dependence.
| This quarter | Last quarter | A year ago | YoY | |
|---|---|---|---|---|
| CDMO Small Molecules | 875 | 835 | 471 | +86.0% |
| Affordable Medicines - API | 625 | 654 | 617 | +1.3% |
| Affordable Medicines - FDF | 677 | 502 | 518 | +30.7% |
| Laurus Bio | 29 | 35 | 47 | −38.3% |
Source: transcript p.7, p.9, p.53
| This quarter | YoY | |
|---|---|---|
| Total Revenue | 4233 | +31.0% |
| CDMO Small Molecules Revenue | 1710 | +77.0% |
| Affordable Medicines Revenue | 2458 | +13.0% |
| Laurus Bio Revenue | 64 | −16.0% |
| EBITDA | 1406 | +78.0% |
| PAT | 899 | +151.0% |
Source: transcript p.7, p.9, p.11, p.13
| Metric | Guidance | For | Against earlier guidance |
|---|---|---|---|
| capex | 3000 | FY2027-FY2028 | was maintained |
| gross_margin | 60 | FY2027 | was maintained |
| ebitda_margin | 30 | FY2027 | was maintained |
| annual_capex_runrate | 1500 | FY2027-FY2028 | unchanged or first given |
Held for next quarter's said-then-did check.
| Question | Answer | Answered? |
|---|---|---|
| Sustainability of elevated CDMO revenues and whether Q2 includes one-off commercial supply campaigns. | Management stated growth is supported by commercialized projects and volume demand, while maintaining full year gross margin target above 60%. | yes |
| Timeline for Laurus Bio expansion and recovery in fermentation revenue after 38% YoY decline. | Bio decline was due to campaign phasing; the 500,000 L Bio4 facility remains on track for Q4 FY27 commissioning. | yes |
| Capital expenditure cadence and funding plans for the ₹3,000 crore 2-year capex plan. | Annual capex run-rate will be ~₹1,500 crore, fully funded via internal cash accruals and operational leverage. | yes |
Laurus Labs reported Q2 FY27 revenue of ₹2,206 crore, up 33% YoY, and PAT of ₹436 crore, up 124% YoY. Growth was driven by the CDMO division, which increased 86% YoY to ₹875 crore, alongside expansion in finished dosage formulations. Operating leverage moved gross margin to 63% and EBITDA margin to 34.5%, while operational cash flows reduced net debt to EBITDA ratio to 1.02x. The results reflect ongoing commercialization of late-stage programs and capacity additions in peptides. Unresolved areas include quarterly revenue fluctuations in Laurus Bio due to campaign phasing and the ramp-up schedule for newly commissioned peptide manufacturing blocks.
What matters most. Commercial execution in high-margin CDMO small molecules and peptides along with disciplined capex deployment.
What would change it. A sharp drop in CDMO commercial orders or delays in commissioning the Bio4 fermentation plant.
| Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,195 cr | ₹1,440 cr | ₹1,195 cr | ₹1,224 cr | ₹1,415 cr | ₹1,720 cr | ₹1,570 cr | ₹1,653 cr | ₹1,778 cr | ₹1,812 cr | ₹2,026 cr | ₹2,206 cr |
| YoY | — | — | +1% | 0% | +18% | +19% | +31% | +35% | +26% | +5% | +29% | +33% |
| EBITDA margin | 15.1% | 16.7% | 14.3% | 14.5% | 20.1% | 24.5% | 24.3% | 24.4% | 27.0% | 28.3% | 31.5% | 34.0% |
| Other income, % of PBT | 6% | 18% | 17% | 22% | 7% | 19% | 4% | 10% | 2% | 3% | 2% | 2% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 27% | 30% | 34% | 22% | 31% | 25% | 28% | 28% | 22% | 22% | 25% | 26% |
| Net profit | ₹23.0 cr | ₹75.0 cr | ₹13.0 cr | ₹20.0 cr | ₹93.0 cr | ₹233 cr | ₹162 cr | ₹194 cr | ₹252 cr | ₹282 cr | ₹362 cr | ₹436 cr |
| YoY | — | — | −52% | −46% | +304% | +211% | +1,146% | +872% | +171% | +21% | +123% | +124% |
| Core profit YoY | — | — | −59% | −65% | +270% | +188% | +1,327% | +1,249% | +163% | +38% | +121% | +138% |
| EPS | ₹0.43 | ₹1.40 | ₹0.23 | ₹0.37 | ₹1.71 | ₹4.33 | ₹3.02 | ₹3.61 | ₹4.66 | ₹5.17 | ₹6.81 | ₹8.17 |
| Flags | · | · | ✓ | ✓ | 1 | 1 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.